Age‑Appropriate Use of Ofloxacin Ophthalmic Drops in Pediatric Conjunctivitis

Guideline Recommendations

• The American Academy of Pediatrics recommends that topical fluoroquinolones, including ofloxacin, are approved for the treatment of acute bacterial conjunctivitis in children older than 12 months. This aligns with FDA labeling and establishes a minimum age threshold of 1 year for initiating ofloxacin ophthalmic therapy. 1

Safety Profile

• Systemic toxicity is not a concern with topical ophthalmic fluoroquinolone therapy, distinguishing it from oral or intravenous formulations. (Evidence based on pediatric guideline review.) 2

Therapeutic Options for Children ≥ 1 Year

• Ofloxacin ophthalmic drops are an appropriate topical fluoroquinolone option for bacterial conjunctivitis in children ≥ 1 year, and may be used alongside other agents such as ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin. (Guideline consensus.) 3
• Selection among these fluoroquinolones should consider the suspected pathogen profile, drug efficacy, tolerability, and cost to optimize treatment outcomes. (Guideline consensus.) 2

Alternative Treatments for Neonates (< 1 Year)

• For neonatal conjunctivitis (ophthalmia neonatorum), clinicians should use alternative antimicrobial agents that have established safety profiles in infants younger than 1 year, rather than ofloxacin ophthalmic drops. (Expert recommendation.) 4